Why "The Lowest Dose for the Shortest Time Possible" Is No Longer the Standard
Are you on hormone therapy and ever been told (by usually unsolicited advice) to take "the lowest dose possible for the shortest amount of time”? You received outdated advice by almost 10 years. That phrase, which became the universal caution attached to every hormone therapy conversation for over two decades, has been formally retired by The Menopause Society, The British Menopause Society, and The International Menopause Society.
The Menopause Society (formerly the North American Menopause Society, or NAMS) explicitly addressed this in its 2017 position statement and doubled down in the landmark 2022 Hormone Therapy Position Statement: the previous guidance that hormone therapy should be prescribed only for the lowest dose for the shortest period of time "may be inadequate or even harmful for some women." It has been replaced with a more precise and clinically meaningful framework. This framework, is the one I use every day in my practice, is built around individualization, shared decision-making, and the concept of the hormone type, appropriate dose, duration, and route of administration. This can only be determined between the patient and her provider who is menopause-literate.
To understand why this matters, and why it took so long to correct, you have to understand where that phrase came from in the first place. So, let’s dive in!
Where the Phrase Came From: The Women's Health Initiative and a Mis-Interpreted Study (but not a bad one, and I’ll tell you why later)
In July 2002, the estrogen-plus-progestin arm of the Women's Health Initiative (WHI) was halted early. This was a landmark study because it was the largest study on hormone therapy, to date, and it was one that was federally funded. The announcement triggered headlines that hormone therapy caused breast cancer and heart disease, and within months, prescriptions plummeted across the country - down to 3-4% of women whereas previously about 40% of menopausal women were using hormone therapy. Women stopped their medications overnight. Physicians stopped prescribing. Medical education pivoted toward caution and frankly - avoidance. Therefore, a generation of practitioners were trained under the assumption that hormones were fundamentally dangerous - myself included.
The problem was not that the WHI findings were fabricated. The problem was that they were profoundly misinterpreted and recklessly overgeneralized. You have to understand research methodology to understand this, but just take my word for it. The study was not powered, nor designed, for what it inaccurately reported.
The women enrolled in the WHI were, on average, 63 years old. This is more than a decade past the typical age of menopause onset which is 52 in the US. The study used a single oral formulation of conjugated equine estrogen combined with synthetic medroxyprogesterone acetate, both of these taken orally. Medroxyprogesterone acetate is a progestin (synthetic progesterone) that we now know carries a different risk profile than other formulations and routes. The trial was not designed to evaluate whether hormone therapy relieved menopause symptoms or was safe for recently menopausal women. In fact, only 12% of women in this study reported they had bothersome menopausal symptoms! The study was designed to evaluate chronic disease prevention, specifically heart disease, in an older population. This study came on the heels of the Nurses Health Study which showed that the risk of major coronary artery disease (ie the type of heart disease that causes heart attacks) among women who took hormone therapy. However, the age of women at the start of the Nurses Health Study were 30-55 years old, NOT the average age of 63 that was the study population in the Women’s Health Initiative. These paint 2 very different stories!
The breast cancer finding, which by the way was the statistic that caused the most alarm, was reported in ways that made a small absolute risk sound catastrophic. Women who received estrogen alone, in the separate arm of the WHI, actually showed a reduction in breast cancer risk, a finding that received far less attention and that was still being collected when the panic set in. Meanwhile, a 2013 analysis estimated that between 2002 and 2012, as many as 91,000 postmenopausal women in the United States died prematurely from conditions that hormone therapy might have helped prevent: cardiovascular disease, osteoporosis, and the long-term consequences of untreated menopause. (Insert the SMDH emoji).
Out of this environment, "the lowest dose for the shortest time possible" was born. It was not based on rigorous evidence that shorter duration and lower dosing produced better outcomes. It was a liability shield dressed up as clinical guidance. GROSS!
Why That Phrase Was Always Clinically Problematic
Setting aside where it came from, the "lowest dose, shortest time" framework had practical problems that compounded over years of application.
> It prioritized risk avoidance over adequate treatment. A dose low enough to avoid a theoretical risk might not be high enough to actually relieve symptoms, improve sleep, protect bone density, or provide the cardiovascular protection that estrogen offers when initiated at the right time. Undertreated menopause is not a safe outcome. Undertreated menopause is a different set of harms, just less visible ones.
>It created unnecessary urgency to discontinue. Women were often told, sometimes abruptly, to stop hormone therapy at age 60 or 65 simply because they had crossed an arbitrary age threshold …. not because their symptoms had resolved, not because their risk profile had changed, and not because evidence supported that stopping improved outcomes. Many experienced immediate return of symptoms, sleep disruption, and significant declines in quality of life.
>It applied a one-size-fits-all cap to an inherently individual decision. A 52-year-old with severe vasomotor symptoms and early-onset osteoporosis, has a fundamentally different benefit-risk calculation than a 68-year-old initiating hormone therapy for the first time. The "lowest dose, shortest time" framework treated them the same. We don’t do this in other areas of medicine - we don’t do this with high blood pressure treatment, we don’t do this with cholesterol treatment, we don’t do this was hip replacement - all those things we base treatment on risk/benefit analysis.
>It left women with premature menopause drastically undertreated. This is the one that makes my blood pressure go up (seriously - I have a very reactive BP!) Women with premature ovarian insufficiency or surgically induced menopause - or frankly menopause before age 45 face significantly elevated risks of cardiovascular disease, osteoporosis, cognitive decline, and depression associated with estrogen deficiency. How do we appropriately mitigate the risks of these disease that cause morbidity and mortality? Treat them with hormone therapy. For these women, limiting treatment to the lowest dose for the shortest time is not caution. It is harm.
What The Menopause Society Says Instead
The Menopause Society's 2022 Hormone Therapy Position Statement is the most authoritative clinical guidance document on this topic in the United States, and it is endorsed by more than 20 international medical organizations. They have repalced the "lowest dose, shortest time" framing with a framework built around four individualized dimensions:
>Appropriate dose. Not the lowest dose possible, but the dose that effectively manages a woman's symptoms and meets her treatment goals. For some women, that may be a low dose. For others, adequate symptom relief and bone protection will require a higher dose. The goal is effectiveness.
>Appropriate duration. Not the shortest time possible, but the duration that is warranted by the individual woman's symptoms, quality of life, and ongoing benefit-risk assessment. The 2022 position statement explicitly states that hormone therapy does not need to be routinely discontinued in women over 60 or 65. A risk/benefit discussion with a knowledgeable clinician, and shared decision making, is how to approach those in their 6th, 7th, 8th (and beyond) decades of life.
>Appropriate regimen. The choice between estrogen alone or estrogen plus a progestogen, and the specific type of progestogen used, depends on whether a woman has a uterus, how she tolerates progestogens, and on her individual risk profile. Micronized progesterone, for example, has a more favorable safety profile than synthetic progestins but it is not tolerated by all women. Progesterone cream through the skin should be avoided, because it does not provide adequate uterine protection.
>Appropriate route of administration. Transdermal estrogen, delivered through a patch, gel, or spray applied to the skin, bypasses first-pass liver metabolism and is associated with lower risks of clots and strokes compared to oral estrogen. However, oral estrogen is a very appropriate option in some women! For women with elevated clotting risk or cardiovascular concerns, transdermal delivery is meaningfully safer. Route of administration is a clinical decision - not a treatment algorithm or what your Reddit thread told you to do.
These four dimensions together define the current standard: not the minimum treatment that avoids liability, but the right treatment for this particular woman, at this particular stage, with this particular history and risk profile. We do this in many other areas of medicine; it is my lifelong dream that we can eventually do this with menopause.
The Timing Hypothesis: When You Start Matters
I told you I’d tell you why the WHI wasn’t all bad - it gave us The Timing Hypothesis!
The timing hypothesis holds that the cardiovascular and cognitive effects of hormone therapy depend critically on when a woman begins treatment. Estrogen applied to a healthy, perimenopausal or recently menopausal blood vessels that are still responsive and not yet significantly diseased appears to be protective. It supports endothelial function, maintains favorable lipid profiles, and may reduce the risk of coronary heart disease. Estrogen initiated more than ten years after menopause onset, or after age 60, in women whose cardiovascular system has already undergone years of age-related and estrogen-deprivation-related change, does not carry the same benefits and may carry greater risk. Hence, timing matters.
This is why the WHI results looked the way they did. The average participant was 63, more than a decade past menopause, with blood vessels that had long since lost its estrogen-responsive window. Applying those findings to a 40-year-old or 50-year-old perimenopausal or recently menopausal woman was like studying the effects of a medication in the wrong population entirely and then telling everyone else not to take it.
The 2022 position statement formalizes the timing hypothesis into clinical practice: for most healthy, symptomatic women under the age of 60 and within 10 years of menopause onset, the benefits of hormone therapy likely outweigh the risks. This is not a fringe position. It is the consensus of the leading experts in menopause medicine, supported by decades of subsequent research and reanalysis of the WHI data. I believe there’s been over 80 papers published on post-WHI data thus far?!
The Bigger Picture
Wow, that was very long winded and if you made it this far, bravo. These words and this data is what all circles in my head when a woman says - well someone told me to use the “lowest dose for the shortest duration possible”, or they say “didn’t a study show that it causes heart attacks and strokes”? I do my damnest to explain this in 5-10 minutes. Most of the time people just look at my speechless, lol. Maybe I should work on my elevator pitch for this topic.
However, the retirement of "lowest dose, shortest time" is not just a guideline update. It is a correction of a medical error that affected millions of women, and a signal that menopause care is finally being taken seriously as a clinical discipline.
Women spent decades being undertreated, not because science supported undertreating them, but because a misread study generated fear that calcified into policy before the evidence could catch up. The Menopause Society's current position makes clear that adequately treating menopausal symptoms is a legitimate and important clinical goal.
The right dose, for the right duration, by the right route, for the individual woman in front of you. That is the standard now. And it was looooong overdue.
This article is based on The Menopause Society's 2022 Hormone Therapy Position Statement and related clinical literature. It is intended for educational purposes and does not constitute medical advice. Decisions about hormone therapy should be made in partnership with a knowledgeable healthcare provider who can evaluate your individual history, symptoms, and risk profile. You can find a menopause specialist by going to menopause.org or isswsh.org.
